Literature DB >> 20516428

Immune regulation of cancer.

Mary L Disis1.   

Abstract

Innate and adaptive immune system cells play a major role in regulating the growth of cancer. Although it is commonly thought that an immune response localized to the tumor will inhibit cancer growth, it is clear that some types of inflammation induced in a tumor may also lead to cancer proliferation, invasion, and dissemination. Recent evidence suggests, however, that some patients with cancer can mount an antitumor immune response that has the potential to control or eliminate cancer. Indeed, a so-called "immune response" signature has been described in malignancy that is associated with improved outcomes in several tumor types. Moreover, the presence of specific subsets of T cells, which have the capability to penetrate tumor stroma and infiltrate deep into the parenchyma, identifies patients with an improved prognosis. Immune-based therapies have the potential to modulate the tumor microenvironment by eliciting immune system cells that will initiate acute inflammation that leads to tissue destruction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20516428      PMCID: PMC3041789          DOI: 10.1200/JCO.2009.27.2146

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  72 in total

1.  Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection.

Authors:  Qiang Gao; Shuang-Jian Qiu; Jia Fan; Jian Zhou; Xiao-Ying Wang; Yong-Sheng Xiao; Yang Xu; Yi-Wei Li; Zhao-You Tang
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

2.  Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Authors:  Suzanne M Garland; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonzalo Perez; Diane M Harper; Sepp Leodolter; Grace W K Tang; Daron G Ferris; Marc Steben; Janine Bryan; Frank J Taddeo; Radha Railkar; Mark T Esser; Heather L Sings; Micki Nelson; John Boslego; Carlos Sattler; Eliav Barr; Laura A Koutsky
Journal:  N Engl J Med       Date:  2007-05-10       Impact factor: 91.245

3.  Biologic predictors in follicular lymphoma: importance of markers of immune response.

Authors:  Todd Kelley; Rose Beck; Ahmed Absi; Tao Jin; Brad Pohlman; Eric Hsi
Journal:  Leuk Lymphoma       Date:  2007-12

Review 4.  The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages.

Authors:  Paola Allavena; Antonio Sica; Graziella Solinas; Chiara Porta; Alberto Mantovani
Journal:  Crit Rev Oncol Hematol       Date:  2007-10-29       Impact factor: 6.312

Review 5.  The sound of silence: modulating anergy in T lymphocytes.

Authors:  Samuel D Saibil; Elissa K Deenick; Pamela S Ohashi
Journal:  Curr Opin Immunol       Date:  2007-10-18       Impact factor: 7.486

6.  Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.

Authors:  Junzo Hamanishi; Masaki Mandai; Masashi Iwasaki; Taku Okazaki; Yoshimasa Tanaka; Ken Yamaguchi; Toshihiro Higuchi; Haruhiko Yagi; Kenji Takakura; Nagahiro Minato; Tasuku Honjo; Shingo Fujii
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-21       Impact factor: 11.205

7.  Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.

Authors:  Pratima Sinha; Virginia K Clements; Stephanie K Bunt; Steven M Albelda; Suzanne Ostrand-Rosenberg
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

Review 8.  Mechanism of action and other potential roles of an immune response modifier.

Authors:  Anthony A Gaspari
Journal:  Cutis       Date:  2007-04

Review 9.  BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.

Authors:  Christopher R Flowers
Journal:  Expert Rev Vaccines       Date:  2007-06       Impact factor: 5.217

10.  Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.

Authors:  Monica C Panelli; Mitchell E Stashower; Herbert B Slade; Kina Smith; Christopher Norwood; Andrea Abati; Patricia Fetsch; Armando Filie; Shelley-Ann Walters; Calvin Astry; Eleonora Aricó; Yingdong Zhao; Silvia Selleri; Ena Wang; Francesco M Marincola
Journal:  Genome Biol       Date:  2007       Impact factor: 13.583

View more
  177 in total

1.  Lenalidomide enhances anti-myeloma cellular immunity.

Authors:  Katarina Luptakova; Jacalyn Rosenblatt; Brett Glotzbecker; Heidi Mills; Dina Stroopinsky; Turner Kufe; Baldev Vasir; Jon Arnason; Dimitri Tzachanis; Jeffrey I Zwicker; Robin M Joyce; James D Levine; Kenneth C Anderson; Donald Kufe; David Avigan
Journal:  Cancer Immunol Immunother       Date:  2012-06-24       Impact factor: 6.968

Review 2.  Latest advances in chemotherapeutic, targeted, and immune approaches in the treatment of metastatic melanoma.

Authors:  Darshil J Shah; Roxana S Dronca
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

3.  Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer.

Authors:  Rayjean J Hung; Cornelia M Ulrich; Ellen L Goode; Yonathan Brhane; Kenneth Muir; Andrew T Chan; Loic Le Marchand; Joellen Schildkraut; John S Witte; Rosalind Eeles; Paolo Boffetta; Margaret R Spitz; Julia G Poirier; David N Rider; Brooke L Fridley; Zhihua Chen; Christopher Haiman; Fredrick Schumacher; Douglas F Easton; Maria Teresa Landi; Paul Brennan; Richard Houlston; David C Christiani; John K Field; Heike Bickeböller; Angela Risch; Zsofia Kote-Jarai; Fredrik Wiklund; Henrik Grönberg; Stephen Chanock; Sonja I Berndt; Peter Kraft; Sara Lindström; Ali Amin Al Olama; Honglin Song; Catherine Phelan; Nicholas Wentzensen; Ulrike Peters; Martha L Slattery; Thomas A Sellers; Graham Casey; Stephen B Gruber; David J Hunter; Christopher I Amos; Brian Henderson
Journal:  J Natl Cancer Inst       Date:  2015-08-29       Impact factor: 13.506

4.  Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy.

Authors:  Diana C Márquez-Garbán; Gang Deng; Begonya Comin-Anduix; Alejandro J Garcia; Yanpeng Xing; Hsiao-Wang Chen; Gardenia Cheung-Lau; Nalo Hamilton; Michael E Jung; Richard J Pietras
Journal:  J Steroid Biochem Mol Biol       Date:  2019-06-19       Impact factor: 4.292

5.  Multimodal cancer care research.

Authors:  N Macdonald
Journal:  Curr Oncol       Date:  2013-12       Impact factor: 3.677

6.  Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Authors:  Xiaohong Wu; Govind Ragupathi; Katherine Panageas; Feng Hong; Philip O Livingston
Journal:  Clin Cancer Res       Date:  2013-07-05       Impact factor: 12.531

7.  CORR Insights®: Intratibial Injection Causes Direct Pulmonary Seeding of Osteosarcoma Cells and Is Not a Spontaneous Model Metastasis: A Mouse Osteosarcoma Model.

Authors:  Daniel M Lerman
Journal:  Clin Orthop Relat Res       Date:  2018-07       Impact factor: 4.176

8.  The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review.

Authors:  Reza Bayat Mokhtari; Narges Baluch; Tina S Homayouni; Evgeniya Morgatskaya; Sushil Kumar; Parandis Kazemi; Herman Yeger
Journal:  J Cell Commun Signal       Date:  2017-07-23       Impact factor: 5.782

9.  Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.

Authors:  Wissam Beaino; Jessie R Nedrow; Carolyn J Anderson
Journal:  Mol Pharm       Date:  2015-05-08       Impact factor: 4.939

10.  Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis.

Authors:  Marieta Toma; Rebekka Wehner; Anja Kloß; Linda Hübner; Georgia Fodelianaki; Kati Erdmann; Susanne Füssel; Stefan Zastrow; Matthias Meinhardt; Barbara Seliger; Dorothee Brech; Elfriede Noessner; Torsten Tonn; Knut Schäkel; Martin Bornhäuser; Michael P Bachmann; Manfred P Wirth; Gustavo Baretton; Marc Schmitz
Journal:  Oncoimmunology       Date:  2015-03-02       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.